The FINANCIAL -- The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection. …
Read More »
The FINANCIAL -- The University of Oxford, in collaboration with AstraZeneca plc, today announces interim trial data from its Phase III trials that show its candidate vaccine, ChAdOx1 nCoV-2019, is effective at preventing COVID-19 (SARS-CoV-2) and offers a high level of protection. …
You might be interested in
When the CDC’s eviction moratorium is lifted, 11 million Americans will face housing instability. As many as 11 million Americans currently…
Shvidi, a local company that has established itself on the Transcaucasian market as a major importer and distributor…
Many vaccinated adults have started going maskless, but most children still cannot. Some states are now fully open. According to…
Magistri, one of the leading security companies in Georgia, continues to offer exceptional security solutions to customers in Georgia: this…